GILEAD SCIENCES SL
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Phase II Comparator Study of Substitution of Tenofovir or Abacavir Receiving Thymidine Analogue as Part of HAART.
Phase 2
Completed
- Conditions
- HIV
- First Posted Date
- 2005-12-28
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT00270556
Evaluation of Chronic HBV Patients w/Evidence of HBV Replication and Normal or Minimally Elevated Liver Transaminases.
Completed
- Conditions
- Chronic Hepatitis B
- First Posted Date
- 2005-12-09
- Last Posted Date
- 2009-02-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT00263614
- Locations
- 🇺🇸
Gilead Sciences, Inc., Foster City, California, United States
Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT00224445
- Locations
- 🇺🇸
Gilead Sciences, Inc., Foster City, California, United States
Combination of Efavirenz and Truvada - COMET Study
Phase 4
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 400
- Registration Number
- NCT00224458
ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1231
- Registration Number
- NCT00208299
- Locations
- 🇺🇸
Multiple study locations (see Central Contact); CV Therapeutics, Inc., Palo Alto, California, United States
ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 787
- Registration Number
- NCT00208312
- Locations
- 🇺🇸
Multiple study locations (see Central Contact); CV Therapeutics, Inc., Palo Alto, California, United States
Observational Study of the Durability of Seroconversion Chronic HBV Patients Who Seroconverted in a Previous Gilead-Sponsored Study of ADV.
Completed
- Conditions
- Hepatitis B
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-01-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 107
- Registration Number
- NCT00158717
Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz.
Phase 3
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 180
- Registration Number
- NCT00158821
Continued Access Study of Adefovir Dipivoxil (ADV) for Patients w/Chronic HBV Infection.
Not Applicable
Terminated
- Conditions
- Hepatitis B
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2007-03-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 400
- Registration Number
- NCT00158704
Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment
Phase 3
Completed
- Conditions
- Invasive AspergillosisOther Fungal Infections
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2005-11-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 800
- Registration Number
- NCT00158730
© Copyright 2025. All Rights Reserved by MedPath